Aduro Biotech Inc. (NASDAQ:ADRO) shares were up 2.3% during trading on Wednesday . The company traded as high as $15.77 and last traded at $15.61, with a volume of 59,074 shares traded. The stock had previously closed at $15.26.

Several research firms have recently issued reports on ADRO. Zacks Investment Research cut Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Roth Capital restated a “buy” rating and issued a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Canaccord Genuity restated a “buy” rating and issued a $30.00 price objective on shares of Aduro Biotech in a report on Friday, August 5th. FBR & Co restated a “buy” rating on shares of Aduro Biotech in a report on Friday, April 29th. Finally, Leerink Swann restated an “outperform” rating and issued a $14.00 price objective (down previously from $48.00) on shares of Aduro Biotech in a report on Tuesday, May 17th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $22.00.

The firm’s 50 day moving average is $14.26 and its 200 day moving average is $13.21. The stock’s market capitalization is $938.61 million.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.21. The firm earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. The company’s quarterly revenue was up 306.3% on a year-over-year basis. Equities research analysts forecast that Aduro Biotech Inc. will post ($1.15) EPS for the current year.

In related news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $15.18, for a total transaction of $379,500.00. Following the completion of the transaction, the insider now owns 12,500 shares in the company, valued at approximately $189,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC increased its stake in Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned 1.35% of Aduro Biotech worth $24,069,000 as of its most recent filing with the SEC.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.